UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Common Stock, $0.00001 par value CTMX The Nasdaq Global Select Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2021 Earnings Conference Call November 4, 2021 5:00 PM ET Company Participants Chau Cheng - Vice President Investor Relations & Corporate Communications Sean McCarthy - President, Chief Executive Officer & Chairman Carlos Campoy - Chief Financial Officer Conference Call Participants Anupam Rama - JP Morgan Roger Song - Jefferies Joe Catanzaro - Piper Sandler Operator Good afternoon, ladies and gentlemen. Thank you for standing by and welcome to CytomX Therapeutics ...

Conditionally Activated Therapeutics for the treatment of cancer 1 © 2020 CytomX Therapeutics, Inc. Forward-Looking Statements This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, preclinical and clinical pipeline and milestones, regulatory obj ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.00001 par value per share CTMX Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE S ...

Conditionally Activated Therapeutics for the treatment of cancer 1 © 2020 CytomX Therapeutics, Inc. Forward-Looking Statements This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, preclinical and clinical pipeline and milestones, regulatory obj ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2021 Earnings Conference Call August 5, 2021 5:00 PM ET Company Participants Chau Cheng - Vice President Investor Relations & Corporate Communications Sean McCarthy - President, Chief Executive Officer & Chairman Amy Peterson - Chief Development Officer Carlos Campoy - Chief Financial Officer Conference Call Participants Anupam Rama - JP Morgan Roger Song - Jefferies Joe Catanzaro - Piper Sandler Cynthia Chen - Cowen Paul Jeng - Guggenheim Peter Lawson - Barclays ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 27-3521219 (State or other jurisdiction of incorporation or organiz ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 | --- | --- | --- | |---------------------------------------------------------------------------------------|----------------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |-----------------------------------------------------------------------|----------------------------------------------------------------------------------|------------------ ...

39th Annual J.P. Morgan Healthcare Conference Sean McCarthy, D.Phil. President, Chief Executive Officer, and Chairman JANUARY 14, 2021 © 2021 CytomX Therapeutics, Inc. Conditionally-Active Antibody Therapeutics for the treatment of cancer © 2020 CytomX Therapeutics, Inc. Forward-Looking Statements This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements ...